A Phase 4 interventional study of Tafolecimab in Acute Myocardial Infarction (AMI), sponsored by The Affiliated Hospital of Xuzhou Medical University. Not yet recruiting at 13 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by The Affiliated Hospital of Xuzhou Medical University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 196 studies in Myocardial Infarction with a site in China — 64 open to participants now, 73 under way, 8 of them phase 3. Myocardial Infarction · China.
Among the 196 studies in Myocardial Infarction with a site in China, this one is the 33rd largest by planned enrollment of the 107 interventional ones that give a count, is one of 20 that started in 2025, is one of 32 in phase 4, reaches primary completion later than 47 of the 72 other live ones, and was the 140th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →64 of the 196 studies in Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Beijing Hospital · Sites in China
Ages 30–75
Peking University Third Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Beijing Anzhen Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
196 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 22 · Phase 4 32
First in 1999; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,160 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 366 across the 107 interventional studies, 1,000 across the 89 observational. Of the 74 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 196 have an industry lead sponsor. The 10 most frequent:
The Affiliated Hospital of Xuzhou Medical University is the lead sponsor of 71 studies on the registry; 34 are open to participants now.
The Affiliated Hospital of Xuzhou Medical University has 4 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
21 of the studies in Myocardial Infarction with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07381803Phase 3Second Affiliated Hospital, Zhejiang University, School of MedicineThe Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction | 2026-12 |
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT07320625Phase 3Shanghai Zhongshan HospitalEfficacy of Montelukast on STEMl Patients | 2027-02-01 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT05891145Yangzhou UniversityRemimazolam for Postoperative Atrial Fibrillation | 2026-12 |
Add all 21 to your calendar (.ics) → With an account.
Among the 196 studies in Myocardial Infarction with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if drug tafolecimab works to treat participants with acute myocardial infarction (AMI) scheduled for primary percutaneous coronary intervention (PCI). It will also learn about the safety of drug tafolecimab. The main questions it aims to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
AMI diagnosed according to the latest guidelines, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive PCSK9i tafolecimab and standard of care (SoC) of acute myocardial infarction
Drug: Tafolecimab
Participants receive SoC of acute myocardial infarction
450mg of tafolecimab (150mg each one) was injected subcutaneously before primary PCI and then 150mg subcutaneously injected every half a month till totally 12 months.
Rate of major adverse cardiovascular events (MACEs)
MACEs including cardiovascular death, nonfatal myocardial infarction, unplanned ischemia-driven revascularization, nonfatal stroke, hospitalization for heart failure
Time frame: From enrollment to 1 year after primary percutaneous coronary intervention
Number of participants with coronary microvascular dysfunction (CMD)
Measurement of coronary angiography-derived microcirculation resistance index (caIMR)
Time frame: Immediately after primary percutaneous coronary intervention
Number of participants with coronary microvascular dysfunction (CMD)
Infarct size (IS), intramyocardial hemorrhage (IMH) and microvascular obstruction (MVO) assessed by cardiac magnetic resonance
Time frame: 3-7 days after primary percutaneous coronary intervention
Concentration of low density lipoprotein cholesterol (LDL-C)
The measurement of LDL-C level and number of participants reaching the target according to current guidelines
Time frame: Both 1 month and 1 year after primary percutaneous coronary intervention
Rate of malignant arrhythmia
These include sudden cardiac death (SCD), sudden death survival (aborted SCD), appropriate implantable cardioverter defibrillator (ICD) interventions, and persistent ventricular arrhythmias monitored by a 72-hour holter electrocardiogram.
Time frame: 1 month after primary percutaneous coronary intervention
Plan to share: No — Participants do not consent to the data sharing about themselves. IPD involves privacy and ethical issues.
No publications or documents are linked to this record.
Start is estimated for Nov 2025; primary completion for Nov 2027, 24 months later.
Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's planned 24 months is below that.
Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafolecimab
The Affiliated Hospital of Xuzhou Medical University